InMed Pharmaceuticals and the Almac Group have partnered on a proprietary approach to augment current biosynthesis-based methods for cannabinoid production.
 
Over the last several months, InMed and Almac have been engaged in developing a streamlined cannabinoid manufacturing process, specifically optimizing the upstream cannabinoid assembly processes as well as downstream purification, to achieve cost efficient, GMP-grade active pharmaceutical ingredients for prescription-based medications.
 
“InMed’s research and development teams have been working diligently in identifying an approach that integrates several existing pharmaceutical manufacturing processes to enable cannabinoid production,” said Eric Hsu, senior vice president, preclinical research and development, InMed. “An essential part of our effort has been drawing on the extensive experience and ‘best practice’ expertise of leading contract development and manufacturing organizations. Almac brings extensive knowledge and a successful track record to this effort, from early process development to commercial-scale manufacturing. We look forward to continuing our combined efforts in optimizing different aspects of the cannabinoid manufacturing process.”
 
Tom Moody, vice president of technology development and commercialization, Almac, said, “Working with the InMed team on, what we all believe may become, a state-of-the-art approach to cannabinoid manufacturing has been an exciting challenge. Our companies continue to make steady progress in several areas across multi-disciplinary research including enzyme engineering, process design and development and downstream processing.”